Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Short Interest Update

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was the recipient of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 878,500 shares, a growth of 59.4% from the February 28th total of 551,300 shares. Based on an average trading volume of 1,770,000 shares, the short-interest ratio is currently 0.5 days. Currently, 13.7% of the shares of the stock are sold short.

Hedge Funds Weigh In On Tonix Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Commonwealth Equity Services LLC purchased a new position in Tonix Pharmaceuticals in the 4th quarter valued at approximately $40,000. Two Sigma Investments LP acquired a new stake in Tonix Pharmaceuticals in the 4th quarter valued at about $66,000. PFG Investments LLC purchased a new position in shares of Tonix Pharmaceuticals in the 4th quarter valued at about $72,000. Northern Trust Corp acquired a new position in shares of Tonix Pharmaceuticals during the fourth quarter worth about $162,000. Finally, Point72 Asset Management L.P. purchased a new stake in shares of Tonix Pharmaceuticals during the fourth quarter worth approximately $526,000. Institutional investors and hedge funds own 82.26% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. StockNews.com initiated coverage on shares of Tonix Pharmaceuticals in a research note on Monday, February 10th. They set a “sell” rating for the company. Noble Financial restated an “outperform” rating and set a $70.00 price target on shares of Tonix Pharmaceuticals in a report on Thursday, March 20th.

Tonix Pharmaceuticals Trading Up 0.6 %

TNXP traded up $0.13 on Monday, hitting $20.30. The company had a trading volume of 994,815 shares, compared to its average volume of 711,618. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The firm has a market cap of $37.94 million, a P/E ratio of 0.00 and a beta of 2.23. The company’s fifty day moving average price is $18.79 and its 200 day moving average price is $20.20. Tonix Pharmaceuticals has a 1 year low of $6.76 and a 1 year high of $672.00.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($9.77) EPS for the quarter, missing the consensus estimate of ($6.23) by ($3.54). Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The company had revenue of $2.58 million during the quarter, compared to analyst estimates of $3.20 million. As a group, equities analysts expect that Tonix Pharmaceuticals will post -1762.5 earnings per share for the current year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.